Scott Gottlieb, MD 🇺🇸· @ScottGottliebMD · X·· 2026-06-02精选AI 评分60
AI 导读
前FDA局长Scott Gottlieb评论称，中国新规要求技术转移海外前须获批准，但美国药物技术对中国企业开放，后者可解析分子先导物并快速转化为竞争性药物。他认为知识流动呈单向性，即流入中国而非流出。其引用的SCMP报道称，中国在Nexperia和Manus争端后收紧对外技术投资规则。
推荐理由
前FDA局长就中美技术流动方向给出判断，可对照中国最新技术出口新规理解美国药企面临的知识产权处境。
正文
China's new rules require approval before Chinese tech is transferred overseas. But U.S. drug tech is open for Chinese firms to parse for molecular leads that are quickly turned into competing medicine. Knowledge flows in one direction: into China not out
https://www.scmp.com/economy/china-economy/article/3355560/china-tightens-outbound-tech-investment-rules-following-nexperia-and-manus-disputes?UUID=695d883c-c4a4-462e-b490-7675d7da105d&tc=12&tpcc=enlz-chinaeconomicupdate
来源：Scott Gottlieb, MD 🇺🇸 · x.com